Literature DB >> 20586184

[Downregulation of AKR1B10 gene expression in colorectal cancer].

E S Kropotova, R A Tychko, O L Zinov'eva, A F Zyrianova, S L Khankin, V L Cherkes, V A Aliev, S F Beresten', N Iu Oparina, T D Mashkova.   

Abstract

Colorectal cancer is one of the most common cancers in the world. In our work changes of AKR1B1 and AKR1B10 gene expression levels in colorectal tumors were studied. Their potential diagnostic value was previously shown for several other cancer types. These genes encode aldoso reductases, which belong to the aldo-keto reductases superfamily consisting of enzymes capable to reduce numerous aromatic and aliphatic aldehydes and ketones. They are also involved into retinoid metabolism and cancerogenesis. We have carried out comparative analysis of mRNA levels of AKR1B1 and AKR1B10 genes in paired samples of normal and colorectal tumor tissues using RT-PCR and quantitative PCR. We have shown for the first time the decrease of activity of these genes in colorectal carcinomas. Significant reduction of AKR1B10 mRNA level was detected in the most of tumor samples (88%, 65/74) even at the early stages of malignancy, and in more than 60% of cases this downregulation was much higher than 10 folds. The decrease of AKR1B1 mRNA level was shown in 10% of tumors only. Therefore, we have detected quite different mRNA expression patterns in colorectal cancer for these two structurally similar genes. These data could indicate different functional roles of these two genes in colorectum. The significant decrease of AKR1B10 mRNA in most samples of colorectal cancer could be considered as potential diagnostic marker of this type of cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586184

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  10 in total

1.  Altered expression of multiple genes involved in retinoic acid biosynthesis in human colorectal cancer.

Authors:  Ekaterina S Kropotova; Olga L Zinovieva; Alisa F Zyryanova; Vera I Dybovaya; Vladimir S Prasolov; Sergey F Beresten; Nina Yu Oparina; Tamara D Mashkova
Journal:  Pathol Oncol Res       Date:  2014-03-06       Impact factor: 3.201

2.  Regulation of aldo-keto reductases in human diseases.

Authors:  Wei-Dong Chen; Yanqiao Zhang
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810

3.  Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer.

Authors:  Inês Cebola; Joaquin Custodio; Mar Muñoz; Anna Díez-Villanueva; Laia Paré; Patricia Prieto; Susanna Aussó; Llorenç Coll-Mulet; Lisardo Boscá; Victor Moreno; Miguel A Peinado
Journal:  Clin Epigenetics       Date:  2015-07-24       Impact factor: 6.551

Review 4.  Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.

Authors:  Reza Khayami; Seyyed Reza Hashemi; Mohammad Amin Kerachian
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

5.  Replacement of Nitrite in Meat Products by Natural Bioactive Compounds Results in Reduced Exposure to N-Nitroso Compounds: The PHYTOME Project.

Authors:  Simone G van Breda; Karen Mathijs; Harm-Jan Pieters; Virág Sági-Kiss; Gunter G Kuhnle; Panagiotis Georgiadis; Giovanna Saccani; Giovanni Parolari; Roberta Virgili; Rashmi Sinha; Gert Hemke; Yung Hung; Wim Verbeke; Ad A Masclee; Carla B Vleugels-Simon; Adriaan A van Bodegraven; Theo M de Kok
Journal:  Mol Nutr Food Res       Date:  2021-08-27       Impact factor: 6.575

6.  Aldehyde Dehydrogenase 2 Family Member (ALDH2) Is a Therapeutic Index for Oxaliplatin Response on Colorectal Cancer Therapy with Dysfunction p53.

Authors:  Wei-Lin Wang; Uyanga Batzorig; Chin-Sheng Hung; Po-Li Wei; Chien-Yu Huang; Yu-Jia Chang
Journal:  Biomed Res Int       Date:  2022-02-07       Impact factor: 3.411

7.  AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.

Authors:  Marko Hojnik; Nataša Kenda Šuster; Špela Smrkolj; Damjan Sisinger; Snježana Frković Grazio; Ivan Verdenik; Tea Lanišnik Rižner
Journal:  Cancers (Basel)       Date:  2022-02-05       Impact factor: 6.639

8.  A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.

Authors:  Hulin Zhao; Xuetao Dong; Tianxiang Huang; Xueji Li
Journal:  Comput Intell Neurosci       Date:  2022-03-18

9.  Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.

Authors:  Amna Saeed; Syeda Abida Ejaz; Muhammad Sarfraz; Nissren Tamam; Farhan Siddique; Naheed Riaz; Faizan Abul Qais; Samir Chtita; Jamshed Iqbal
Journal:  Molecules       Date:  2022-06-21       Impact factor: 4.927

10.  Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.

Authors:  Yuanwei Guo; Weihao Luo; Zheng Hu; Jia Li; Xiaojie Li; Huiqiu Cao; Jun Li; Bo Wen; Jian Zhang; Hao Cheng; Wangyuan Guo; Tan Tan; Dixian Luo
Journal:  Cell Biosci       Date:  2016-03-05       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.